New Coalition Aims to Expand European Drug Access
A new group is working to bridge the gap in psychiatric treatment access for patients across Europe.
Updated on Oct. 28, 2026 in Mental Health
Live Poll
Should European regulators lower barriers to approve new psychiatric medications more quickly?
A new European coalition has formed to address significant gaps in the availability of psychiatric medications compared to the United States. The group aims to streamline regulatory processes to help patients across Europe access innovative mental health treatments.
Why it matters
Disparities in drug approval rates between the US and Europe leave many patients without access to the latest therapies. This initiative seeks to modernize how regulators evaluate mental health treatments, which currently often rely on standards designed for physical conditions.
Between 2016 and 2025, the FDA approved 38 drugs for mental disorders compared to 11 approvals by the European Medicines Agency. It remains unclear how the coalition will reconcile these divergent approval figures to increase European access.
The players
European Coalition for Mental Health Medicines Innovation
A newly formed group of patient organizations, medical societies, and industry stakeholders working to improve psychiatric drug access.
European Medicines Agency
The European Union agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
US Food and Drug Administration
The federal agency overseeing the safety and efficacy of human drugs, serving here as a benchmark for psychiatric treatment approvals.
The details
The coalition brings together patient organizations, medical societies, and industry representatives to identify regulatory bottlenecks. Current European hurdles include lower drug pricing policies and regulatory requirements that may not fully account for the unique complexities of psychiatric disorders. The group plans to facilitate dialogue between researchers and authorities to align incentives for launching new mental health products in the European market.
Timeline
2015: Annual social and economic costs of mental illness in 28 EU states exceeded €600 billion.
2016-2025: The FDA approved 38 psychiatric drugs while the EMA approved 11.
October 2026: The 39th ECNP Congress occurred in Munich.
Health Landscape
The formation of this coalition follows discussions at the 39th ECNP Congress, marking an intensification of efforts to address long-standing regional drug disparities. This initiative aims to correct a trend where only three US-approved psychiatric therapies are currently reimbursed in five major European nations.
Patients and caregivers should be aware that the availability of specific psychiatric treatments can vary significantly depending on the country of residence. If you are struggling to access a medication approved in other regions, discuss the clinical alternatives and local treatment options with your physician.
The takeaway
The economic and social burden of mental illness remains high, exceeding €600 billion in Europe as of 2015. While waiting for broader policy changes, maintain open communication with your psychiatrist about the most effective, accessible treatments currently available in your area.
Further reading
Learn more about the latest innovations and policy updates in Mental Health.
Source note: This article includes information reported by Medscape.
Live Poll
Should European regulators lower barriers to approve new psychiatric medications more quickly?
